Cancer Partners of Nebraska offers unique access to clinical trials, thanks to our membership in two major National Cancer Institute (NCI) research networks: Alliance, as an MD Anderson Cancer Center affiliate, and ECOG-ACRIN Cancer Research Group.
If you are not able to resolve your concerns with the study doctor or study staff, if you have a complaint, or if you have general questions about what it means to be in a research study, you can call the Cancer Partners of Nebraska Human Research Protection Program at (402) 420-7000, Ext. 202, or email HumanProtections@cancerpartners.com.
Most clinical trials at Cancer Partners are interventional studies, meaning patients are assigned to a treatment or other intervention and their outcomes are measured. See the full list below sorted by type of cancer. If you wish to discuss a specific trial, please discuss it with your oncologist or contact our Research Department at (402) 327-7363.
A PHASE III CLINICAL TRIAL EVALUATING DEESCALATION OF BREAST RADIATION FOR CONSERVATIVE TREATMENT OF STAGE I, HORMONE SENSITIVE, HER2-NEGATIVE, ONCOTYPE RECURRENCE SCORE ≤ 18 BREAST CANCER
Learn MoreA Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO*) *Her2 Radiation Optimization (HERO)
Learn MoreA PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF OP-1250 MONOTHERAPY VS STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST CANCER FOLLOWING ENDOCRINE AND CDK 4/6 INHIBITOR THERAPY (OPERA-01)
The Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
Learn MoreA Phase II/III Randomized Study of R-MiniCHOP with or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC AND BCL2 and/or BCL6 Rearrangements
Learn MoreRandomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed therapy with Venetoclax and Obinutzumab in Newly Diagnosed Asymptomatic High-Risk Patient with DLL/CLL: EVOLVE CLL/SLL Study.
Learn MoreA Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma not Intended for Early Autologous Transplantation
The Multiple Myeloma Disease Registry
Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as post-autologous stem cell transplant maintenance therapy in patients with MM using minimal residual disease to direct therapy duration (DRAMMATIC STUDY).
Learn MoreCOLON ADJUVANT CHEMOTHERAPY BASED ON EVALUATION OF RESIDUAL DISEASE (CIRCULATE-NORTH AMERICA)
Learn MoreRandomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Learn MoreA Randomized, Open-label Study of HLX10 plus Chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus Chemotherapy in Previously Untreated US Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Stage II-III Resected NSCLC – Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Learn MoreIntegration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST CHEMO-IO (ACCIO)
Learn MoreColon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA)
Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST CHEMO-IO (ACCIO)
Learn MoreA Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC)
Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy
Learn MoreA Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine Tumors
MAPK Pathway Altered Malignancies – Expanded Ulixertinib (BVD-523) access in Patients with Advanced MAPK Pathway-Altered Malignancies.
Starting Immunotherapy- Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
The list of available biomarker studies is always changing. Please contact Cancer Partners Research Department for the most current list.
